Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.44 |
| ▸ | ESR1 | P03372 | 5/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA3 | P07451 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | PGR | P06401 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2185739 | 0.79 | GRM5 (0.40) | APPLMNACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3573293 | 0.78 | APP (0.48) | APPLMNACYP3A4MAPTALOX15 | |
| SCHEMBL1230907 | 0.76 | APP (0.48) | APPESR1CA12CA2CA3 | |
| SCHEMBL5687827 | 0.75 | P2RY6 (0.32) | P2RY6 | |
| SCHEMBL16924578 | 0.75 | ALDH1A1 (0.41) | LMNAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL15062769 | 0.73 | PTPN11 (0.50) | CA12CA2CA9CA14MAPT | |
| SCHEMBL7033211 | 0.71 | APP (0.48) | APPESR1CA12CA2CA3 | |
| SCHEMBL14400750 | 0.71 | APP (0.74) | APPESR1CA12CA2CA3 | |
| SCHEMBL673609 | 0.71 | APP (0.74) | APPESR1CA12CA2CA3 | |
| SCHEMBL30283030 | 0.71 | APP (0.44) | APPESR1CA12CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100304381-A1 | FLUORESCENT NUCLEOBASE CONJUGATES HAVING ANIONIC LINKERS | Life Technologies Corporation (US) | 2010-12-02 | — | — | US | disclosed |
| US-7687236-B2 | Fluorescent nucleobase conjugates having anionic linkers | APPLIED BIOSYSTEMS, LLC (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1317464-B1 | FLUORESCENT NUCLEOBASE CONJUGATES HAVING ANIONIC LINKERS | APPLERA CORP (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20090092986-A1 | Fluorescent Nucleobase Conjugates Having Anionic Linkers | APPLIED BIOSYSTEMS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-7429651-B2 | Fluorescent nucleobase conjugates having anionic linkers | APPLERA CORPORATION (US) | 2008-09-30 | — | — | US | disclosed |
| US-20050250119-A1 | Fluorescent nucleobase conjugates having anionic linkers | APPLERA CORPORATION (US) | 2005-11-10 | — | — | US | disclosed |
| US-6811979-B2 | NUCLEOTIDE DERIVATIVE FOR USE IN SEQUENCE DETERMINATION OF NUCLEIC ACID MOLECULE | APPLERA CORPORATION | 2004-11-02 | — | — | US | disclosed |
| EP-1317464-A2 | FLUORESCENT NUCLEOBASE CONJUGATES HAVING ANIONIC LINKERS | Applera Corporation (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20020102590-A1 | Fluorescent nucleobase conjugates having anionic linkers | PE CORPORATION (NY) (US) | 2002-08-01 | — | — | US | disclosed |
| WO-2002030944-A2 | FLUORESCENT NUCLEOBASE CONJUGATES HAVING ANIONIC LINKERS | APPLERA CORPORATION (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250119-A1 | Fluorescent nucleobase conjugates having anionic linkers | DNTT, DUT, NT5C3B | APP 4729/4885ESR1 1781/4885CA12 3307/4885 |
| US-20100304381-A1 | FLUORESCENT NUCLEOBASE CONJUGATES HAVING ANIONIC LINKERS | DNTT, DUT, NT5C3B | APP 4729/4885ESR1 1781/4885CA12 3307/4885 |
| US-20020102590-A1 | Fluorescent nucleobase conjugates having anionic linkers | DNTT, DUT, NT5C3B | APP 4729/4885ESR1 1781/4885CA12 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.